Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Perindopril is a long-acting angiotensin-converting enzyme (ACE) inhibitor used to treat high blood pressure (hypertension), heart failure, and stable coronary artery disease. It works by inhibiting the conversion of angiotensin I to angiotensin II, a hormone that causes blood vessels to constrict. By blocking this process, perindopril relaxes blood vessels, lowers blood pressure, increases urine output and sodium excretion, and reduces the workload on the heart. Perindopril is administered orally as a prodrug and is converted in the liver to its active metabolite, perindoprilat. The drug was patented in 1980 and approved for medical use in 1988[5][6][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on perindopril.